Sean E Collins

1.7k citations

30 papers · 738 indexed · h-index 15

Impact in

Virology top 2%
- HIV Research and Treatment
Infectious Diseases top 2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Tuberculosis Research and Epidemiology

Papers in ⓘ

Virology 20
- HIV Research and Treatment 20
Medical Terminology 1

Co-authors: Hal Martin (12 shared papers)Rima Acosta (6 shared papers)Diana M. Brainard (9 shared papers)Jean W. Pape (5 shared papers)Daniel W. Fitzgerald (3 shared papers)Xuelian Wei (6 shared papers)Paul E. Sax (5 shared papers)Oksana Ocheretina (4 shared papers)
Journals: Open Forum Infectious Diseases (6 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (5 papers)The Lancet HIV (3 papers)PLoS ONE (3 papers)Clinical Infectious Diseases (2 papers)
Partner nations: United States France Haiti

In The Last Decade

Sean E Collins

29 papers receiving 719 citations

Peers

Countries citing papers authored by Sean E Collins

Since Specialization

Citations

This map shows the geographic impact of Sean E Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean E Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean E Collins more than expected).

Fields of papers citing papers by Sean E Collins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean E Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean E Collins. The network helps show where Sean E Collins may publish in the future.

Co-authors

The 25 scholars most cited alongside Sean E Collins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sean E Collins Line = papers co-authored together Sean E Collins links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet HIV ·David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie Thompson, Cynthia Brinson, Debbie Hagins, Moti Ramgopal, Andrea Antinori, Xuelian Wei, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin	2019	116
2	Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet HIV ·Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens, Helmut Albrecht, Paul E. Sax, Franco Maggiolo, Catherine Creticos, Claudia Martorell, Xuelian Wei, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin	2019	99
3	Correlation between Genotypic and Phenotypic Testing for Resistance to Rifampin in Mycobacterium tuberculosis Clinical Isolates in Haiti: Investigation of Cases with Discrepant Susceptibility Results PLoS ONE ·Oksana Ocheretina, Vincent Escuyer, Marie-Marcelle Mabou, Gertrude Royal-Mardi, Sean E Collins, Stalz Charles Vilbrun, Jean W. Pape, Daniel W. Fitzgerald	2014	91
4	Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus Clinical Infectious Diseases ·Paul E. Sax, Jürgen K. Rockstroh, Anne F. Luetkemeyer, Yazdan Yazdanpanah, Douglas Ward, Benoît Trottier, Armin Rieger, Hui Liu, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin, (unknown)	2020	80
5	Gender inequality and HIV transmission: a global analysis Journal of the International AIDS Society ·Eugene T Richardson, Sean E Collins, Tiffany H. Kung, James H. Jones, Khai Hoan Tram, Victoria L. Boggiano, Linda‐Gail Bekker, Andrew Zolopa	2014	63
6	High Mortality among Patients with AIDS Who Received a Diagnosis of Tuberculosis in the First 3 Months of Antiretroviral Therapy Clinical Infectious Diseases ·Serena P. Koenig, Cynthia Riviere, Paul Leger, Patrice Joseph, Patrice Sévère, Kea Parker, Sean E Collins, Erin Lee, Jean W. Pape, Daniel W. Fitzgerald	2009	45
7	Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight PLoS ONE ·Carrie McMahon, James L. Trevaskis, Christoph C Carter, Kevin Holsapple, Kirsten White, Moupali Das, Sean E Collins, Hal Martin, Leigh Ann Burns‐Naas	2020	32
8	Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study JAIDS Journal of Acquired Immune Deficiency Syndromes ·Debbie Hagins, Princy Kumar, Michael S. Saag, Anson K Wurapa, Indira Brar, Daniel Berger, Olayemi Osiyemi, Corrilynn O. Hileman, Moti Ramgopal, Cheryl McDonald, Christiana Blair, Kristen Andreatta, Sean E Collins, Diana M. Brainard, Hal Martin, (unknown)	2021	28
9	Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study The Lancet HIV ·Joseph J. Eron, Susan J. Little, Gordon Crofoot, Paul Cook, Peter Ruane, Dushyantha Jayaweera, Laurie A. VanderVeen, Edwin DeJesus, Yanan Zheng, Anthony Mills, Hailin Huang, Sarah Waldman, Moti Ramgopal, Linda Gorgos, Sean E Collins, Jared M. Baeten, Marina Caskey	2024	24
10	Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance JAIDS Journal of Acquired Immune Deficiency Syndromes ·Rima Acosta, Madeleine Willkom, Kristen Andreatta, Hui Liu, Ross Martin, Aiyappa Parvangada, Hal Martin, Sean E Collins, Kirsten White	2020	20
11	Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients Drugs ·Sean E Collins, Philip Grant, Robert W. Shafer	2015	17
12	Tuberculosis in the aftermath of the 2010 earthquake in Haiti Bulletin of the World Health Organization ·Serena P. Koenig, Vanessa Rouzier, Stalz Charles Vilbrun, Willy Morose, Sean E Collins, Patrice Joseph, Diessy Decome, Oksana Ocheretina, Stanislas Galbaud, Lauren Hashiguchi, Pierrot Julma, Jean W. Pape	2015	16
13	Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a “Low-Level” rpoB Mutation L511P – Insights into a Mechanism of Resistance Escalation PLoS ONE ·Oksana Ocheretina, Li Shen, Vincent Escuyer, Marie-Marcelle Mabou, Gertrude Royal-Mardi, Sean E Collins, Jean W. Pape, Daniel W. Fitzgerald	2015	15
14	Pharmacist’s Counselling Improves Patient Knowledge Regarding Warfarin, Irrespective of Health Literacy Level SHILAP Revista de lepidopterología ·Sean E Collins, Andrew J. Barber, Laura J. Sahm	2014	15
15	High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I AIDS ·Paul E. Sax, Kristen Andreatta, Jean‐Michel Molina, Eric S. Daar, Debbie Hagins, Rima Acosta, Michelle L. D’Antoni, Silvia Chang, Ross Martin, Hui Liu, Christiana Blair, Ian R. McNicholl, Joel E. Gallant, Sean E Collins, Hal Martin, Kirsten White	2022	14
16	Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials JAIDS Journal of Acquired Immune Deficiency Syndromes ·Brian Moldt, Aiyappa Parvangada, Ross Martin, Craig S. Pace, Mini Balakrishnan, N.D. Thomsen, Sean E Collins, Herbert Kuster, Dominique L. Braun, Huldrych F. Günthard, Romas Geleziunas, Christian Callebaut	2021	12
17	Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants Journal of Antimicrobial Chemotherapy ·Rima Acosta, Grace Q Chen, Silvia Chang, Ross Martin, Xinxin Wang, Hailin Huang, Diana M. Brainard, Sean E Collins, Hal Martin, Kirsten White	2021	11
18	Long‐term mortality after tuberculosis treatment among persons living with HIV in Haiti Journal of the International AIDS Society ·Yvetot Joseph, Zhiwen Yao, Akanksha Dua, Patrice Sévère, Sean E Collins, Heejung Bang, Marc Antoine Jean‐Juste, Oksana Ocheretina, Alexandra Apollon, Margaret L. McNairy, Kathryn Dupnik, Etienne Cremieux, Anthony Byrne, Jean W. Pape, Serena P. Koenig	2021	7
19	Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide AIDS ·Paul E. Sax, Edwin DeJesus, Gordon Crofoot, Douglas Ward, Paul Benson, Robin Dretler, Anthony Mills, Cynthia Brinson, Xuelian Wei, Sean E Collins, Andrew Cheng	2018	7
20	1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis Open Forum Infectious Diseases ·Joseph J. Eron, Aimee Wilkin, Moti Ramgopal, Olayemi Osiyemi, Mehri S. McKellar, (unknown), Jihad Slim, David M. Asmuth, Edwin DeJesus, Polina German, Christiana Blair, Christoph C Carter, Diana M. Brainard, Sean E Collins, Hal Martin	2020	6

About Sean E Collins

Sean E Collins is a scholar working on Virology, Medical Terminology, Infectious Diseases, Emergency Medicine and Transplantation, having authored 30 papers that have together received 738 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (20 papers), HIV/AIDS Research and Interventions (13 papers), HIV-related health complications and treatments (7 papers), Tuberculosis Research and Epidemiology (4 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers), Biochemical and Molecular Research (2 papers) and Mycobacterium research and diagnosis (2 papers). The work is most often cited by research in Virology (350 citations), Infectious Diseases (636 citations), Emergency Medicine (246 citations), Epidemiology (204 citations) and Molecular Medicine (19 citations). Sean E Collins has collaborated with scholars based in United States, France and Haiti. Frequent co-authors include Hal Martin, Rima Acosta, Diana M. Brainard, Jean W. Pape, Daniel W. Fitzgerald, Xuelian Wei, Paul E. Sax, Oksana Ocheretina, Yazdan Yazdanpanah and Vincent Escuyer. Their work appears in journals such as Open Forum Infectious Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes, The Lancet HIV, PLoS ONE and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact